I. Rationale and Methods for Studying Adjuvant Systemic Therapy --;1. Evolving concepts in the adjuvant systemic therapy of operable breast cancer --;2. Statistical methods for early breast cancer trials --;II. Results of Clinical Studies --;3. The nature of the benefit --;4. Adjuvant endocrine therapy of breast cancer --;5. Adjuvant chemotherapy of axillary lymph-node-positive breast cancer --;6. The node-negative problem: To treat or not to treat --;III. Special Problems --;7. Defining the high-risk breast cancer patient --;8. Models for weighing benefits and toxicities --;9. Financial considerations in the use of adjuvant chemotherapy --;10. The use of adjuvant therapy in patients treated with conservative surgery and radiotherapy --;11. Treating the relapsed patient --;IV. Future Directions --;12. Unanswered questions in the adjuvant therapy of breast cancer --;13. Neoadjuvant chemotherapy --;14. Altering cell kinetics with endocrine therapy --;15. Polypeptide growth factors: Their potential value in the management of breast cancer patients --;16. Immunotherapy of breast cancer --;17. Breast cancer chemoprevention --;Appendices --;I. Consensus statements from panels convened by The National Cancer Institute in 1980, 1985, 1990 --;II. List of completed and ongoing randomized clinical trials addressing questions related to the use of adjuvant systemic therapy to treat resectable breast cancer.
SUMMARY OR ABSTRACT
Text of Note
The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer.